The study, led by Gretchen A. McNally and Grace Ji-eun Shin of The Ohio State University Comprehensive Cancer Center, tracked 25 adults with non-Hodgkin lymphoma who were beginning first-line chemotherapy with vincristine-containing CHOP or EPOCH regimens. Rather than conducting an artificial clinical-trial setting, the researchers embedded their measurements directly into routine care, drawing blood and administering questionnaires at the same visits where patients received their infusions. Sixteen participants received CHOP, typically delivered in an outpatient infusion lasting about ninety minutes, while nine received EPOCH, which required roughly five days of inpatient admission with continuous drug infusion over 96 hours. The team followed participants through four to six months of chemotherapy, and a small subset of six survivors for an additional 24 to 42 months after treatment ended.

The centerpiece of the research is neurofilament light chain, or NfL, a structural protein that forms part of the internal scaffolding of nerve axons. When axons are injured, NfL leaks into the surrounding fluid and eventually reaches the bloodstream, where it can be quantified with single-molecule array technology capable of detecting concentrations as low as 0.038 picograms per milliliter. Because NfL rises after virtually any form of neuroaxonal damage, from multiple sclerosis to traumatic brain injury, its interpretation requires careful longitudinal context. In the case of vincristine, the biological logic is compelling: the drug disrupts microtubule assembly and axonal transport, the cellular freight system that keeps long peripheral nerves alive, and the resulting distal axonal injury should release NfL into circulation.

That prediction was borne out dramatically. Using mixed-effects statistical models on log-transformed data, the researchers found that model-estimated plasma NfL rose from a geometric mean of 26.3 picograms per milliliter before the first chemotherapy cycle to 91.6 picograms per milliliter before the second cycle, 107.2 before the fourth, and 94.3 before the sixth. Relative to the pretreatment measurement, these values represent increases of roughly 248 to 307 percent, with every timepoint reaching statistical significance at p less than 0.001. Notably, the rise was not a simple cumulative-dose curve of the kind reported for platinum drugs or paclitaxel; instead, NfL surged early and then plateaued at a sustained elevation, a pattern consistent with prior clinical observations that vincristine neuropathy does not track neatly with total cumulative dose.

Alongside the biomarker measurements, patients completed the EORTC QLQ-CIPN20 questionnaire, a validated 20-item instrument capturing sensory, motor, and autonomic neuropathy symptoms, as well as the Brief Pain Inventory Short Form for pain severity. Clinicians recorded neuropathy grades using the National Cancer Institute’s Common Terminology Criteria for Adverse Events as part of standard toxicity documentation. Patient-reported symptom scores climbed significantly during treatment, with the model-estimated CIPN20 score rising 23.4 percent by the time of the sixth cycle compared with baseline. Clinician-graded CTCAE neuropathy also increased, with grade 1 or higher neuropathy documented in a third of participants by the final on-treatment assessment, though the clinician-recorded changes were smaller and less clearly longitudinal than what patients reported about themselves.

The relationship between the blood biomarker and the lived experience of neuropathy proved more nuanced than a simple one-to-one correspondence. When the researchers pooled all paired NfL and CIPN20 observations across treatment visits, they found a modest but statistically significant association, with a repeated-measures correlation of 0.439 and a p value of 0.020 across 51 paired observations. However, at any single timepoint, the two measures did not correlate reliably, and exploratory lagged analyses of whether early NfL change predicted later symptom worsening were inconclusive in the full dataset. A post hoc sensitivity analysis, excluding one participant with extreme symptom severity, hinted that early NfL concentrations might anticipate later patient-reported symptoms, but the authors are careful to frame this as hypothesis-generating rather than proof of predictive value.

This imperfect alignment between biology and symptom is not a failure of the biomarker; it is a window into the complexity of chemotherapy neurotoxicity. Patient-perceived symptoms may emerge before, during, or after detectable NfL release, reflecting not just structural axonal injury but also altered nerve excitability, immune activation, pain sensitization, and functional adaptation. Emerging mechanistic research suggests that NfL itself may not be a passive bystander: a recent study reported that NfL released after neuronal damage can activate myeloid immune cells and promote neuroinflammation, and preclinical work has implicated astrocyte activation, macrophage infiltration, cytokine release, and NLRP3 inflammasome signaling in vincristine-induced pain. NfL may therefore be best understood as one node in a broader injury-and-immune response rather than a same-day readout of symptom severity.

The study also illuminated the messy realities of real-world oncology that biomarker research must eventually confront. A quarter of participants, six of 25, underwent vincristine dose modifications, including reductions, holds, or discontinuations, for reasons ranging from neuropathy to ileus and constipation. Dose-modified participants showed a numerically larger median rise in NfL, approximately 4.3-fold versus 1.75-fold, but paradoxically reported no median increase in CIPN20 scores, while non-modified participants reported a median increase of six points. These exploratory comparisons did not reach statistical significance, but they suggest that clinical decisions to reduce drug exposure reshape both the biology and the symptom trajectory in ways that any future predictive model must account for. Among the six survivors followed two to three and a half years after treatment, patient-reported neuropathy scores remained elevated, ranging from 20 to 36, and the two participants with the highest long-term symptom burden had also experienced dose modification during therapy.

The authors are candid about the limitations of their pilot. Twenty-five participants from a single center constitute a small cohort with substantial missing data, heterogeneous early sampling because some patients were recruited after treatment had already begun, and no standardized neurologic examination, nerve conduction studies, or quantitative sensory testing to validate the biomarker against objective nerve function. NfL concentrations are also influenced by age, kidney function, body size, and neurological comorbidities, all of which complicate interpretation in a small and demographically diverse sample. The clinician-recorded CTCAE grades came from routine care rather than a standardized assessment protocol, introducing provider-level variability. These constraints mean the study cannot establish NfL as a standalone diagnostic or predictive tool, and the authors explicitly caution that larger studies with standardized pretreatment sampling are needed before NfL can inform routine clinical decisions.

What the study does establish is a methodological foundation and a compelling proof of concept. All prespecified feasibility criteria were met: every enrolled participant contributed early assessment data, retention through the final on-treatment timepoint reached 100 percent among those who remained eligible, and the full sampling schedule fit within the six-month treatment window. Plasma NfL proved sensitive to vincristine exposure, rising early and staying elevated, while patient-reported symptoms rose in parallel without perfectly mirroring the biomarker. The most productive path forward, the researchers argue, is not to replace patient questionnaires or clinician grading with a blood test, but to combine all three into a multimodal monitoring framework in which NfL provides biological context that symptoms alone cannot supply. For a growing population of lymphoma survivors facing persistent neuropathy with few treatment options, the prospect of identifying nerve injury early, before symptoms become disabling, represents a meaningful step toward personalized neuroprotection during cancer therapy.

Subject of Research: Neurofilament light chain as a blood biomarker of vincristine-induced peripheral neuropathy in lymphoma chemotherapy

Article Title: Longitudinal plasma neurofilament light chain and patient-reported outcomes as complementary markers of vincristine-associated peripheral neuropathy in adults with lymphoma: a cohort study

Article References: McNally, G. A., Shin, G. J.-E., Worthen-Chaudhari, L., Schnell, P. M., Flora, L., Krishna, S. S., Voorhees, T., Baiocchi, R., Bond, D., Christian, B., Maddocks, K., Sawalha, Y., & Lustberg, M. B. (2026). Longitudinal plasma neurofilament light chain and patient-reported outcomes as complementary markers of vincristine-associated peripheral neuropathy in adults with lymphoma: a cohort study. Journal of Neurology, 273(10), Article 594. https://doi.org/10.1007/s00415-026-14096-2

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14096-2

Keywords: neurofilament light chain, chemotherapy-induced peripheral neuropathy, vincristine, non-Hodgkin lymphoma, biomarker, patient-reported outcomes, CHOP, EPOCH, neuroaxonal injury, survivorship, CTCAE, longitudinal cohort study

The central result is striking in its simplicity. Among the 100 enrolled patients, only 8 percent developed grade 2 acute genitourinary toxicity—defined in this trial as urinary frequency severe enough to require two or more medications—with a 95 percent confidence interval of 2.6 to 13.4 percent. Not a single patient experienced grade 3 or higher acute genitourinary toxicity, and no grade 2 or worse urinary retention, urinary pain, urinary urgency, or hematuria was recorded. Grade 1 urinary frequency, the mildest form, occurred in 46 percent of patients, but even this figure reflects a symptom burden that many patients with enlarged prostates already live with before treatment begins. No acute gastrointestinal adverse events were observed at all, a notable outcome given that rectal toxicity is often the limiting factor in prostate radiotherapy.

The radiobiological logic behind the regimen is what makes the result scientifically interesting. Prostate cancer cells carry an unusually low alpha/beta ratio—estimated at approximately 1.4 Gy—which describes how sensitive a tumor is to the size of each radiation fraction. A low alpha/beta value means the cancer is more vulnerable to large individual doses than the surrounding healthy organs are. Hypofractionation exploits this vulnerability: by delivering bigger doses per session, clinicians can inflict disproportionate damage on tumor cells while the nearby bladder and rectum, which have higher alpha/beta values, theoretically tolerate the schedule better. Conventional fractionated radiotherapy delivers 2.0 Gy per fraction across 38 to 40 sessions over nearly two months; the Japanese trial delivered 51.6 Gy in relative biological effectiveness terms across just 12 sessions in a median overall treatment time of 20 days, with no interruptions or delays in any patient.

Protons add a second layer of physical advantage on top of this radiobiological one. Unlike photon beams, which deposit radiation along their entire path through the body and exit on the far side, protons stop at a depth determined by their energy—the Bragg peak—releasing their maximum dose precisely at the tumor and falling off rapidly beyond it. This means minimal energy is deposited in normal tissue in front of the target and essentially none behind it. The trial used the IBA Proteus ONE system, a compact gantry with spot-scanning beam delivery, and planned treatments in RayStation version 10A using a single-field uniform dose algorithm applied to a beam-specific planning target volume, an approach shown to improve conformity and organ sparing compared with uniform-dose planning target volumes.

The technical preparation was equally meticulous. Before treatment, urologists implanted transperineal ultrasound-guided gold fiducial markers into each patient’s prostate and injected SpaceOAR, a hydrogel spacer that physically separates the prostate from the rectum, reducing the dose the rectal wall receives. Daily treatments began with image-guided bony alignment followed by fiducial-based registration, maintaining positional accuracy within a 1-millimeter margin. Patients were instructed to arrive with a comfortably full bladder and an empty rectum, immobilized supine on a vacuum pad. Simulation used 1-millimeter-thick CT slices fused with 3.0 Tesla MRI. The clinical target volume encompassed the prostate and, depending on risk group, part of the seminal vesicles—none for low-risk patients, the proximal third for intermediate-risk, and the proximal half for high-risk—expanded by 5 to 6 millimeters to form the planning target volume. Elective pelvic lymph node irradiation was deliberately omitted.

The trial’s design reflects a careful, staged approach to safety. Built on Simon’s minimax two-stage design with a significance level of 0.05 and 90 percent power, the protocol set acceptable and unacceptable toxicity thresholds at below 5 percent and above 15 percent respectively. In the first stage, 30 patients were enrolled; only two developed grade 2 genitourinary toxicity, satisfying the continuation criterion. In the second stage, the cohort grew to 83 patients with seven grade 2 events, again passing the checkpoint. A protocol-specified expansion then brought the total to 100 patients. Any grade 4 or 5 normal tissue toxicity would have mandated immediate suspension of the study, an event that never occurred. The researchers also adopted a modified grading system from earlier work by Nakajima and colleagues, because standard CTCAE version 5.0 criteria struggle to distinguish radiation-induced urinary symptoms from the baseline symptoms of benign prostatic hyperplasia, which many older prostate cancer patients already have. Under the modified criteria, one dysuria medication counted as grade 1 and two or more as grade 2.

Perhaps the most puzzling finding is a counterintuitive pattern in the subgroup analysis. Multivariate logistic regression revealed that high-risk patients—those with higher PSA levels, more advanced T stage, or Gleason scores of 8 or above—had a significantly lower likelihood of developing grade 2 genitourinary toxicity than lower-risk patients, with an odds ratio of 0.023 and a P value of 0.042. High-risk patients received both neoadjuvant and adjuvant androgen deprivation therapy, while intermediate-risk patients received neoadjuvant hormone therapy alone. One earlier hypothesis held that androgen deprivation shrinks the prostate and thereby reduces toxicity, but the intermediate-risk group, which also received hormone therapy, did not show the same protective pattern. The authors are candid that the mechanism behind this trend toward low toxicity in the high-risk group is unknown and warrants further investigation.

The analysis also confirmed benign prostatic hyperplasia as an independent risk factor for grade 2 genitourinary toxicity, with an odds ratio of 0.040 and a P value of 0.018. This aligns with clinical intuition: a gland already compromised by enlargement has less functional reserve when radiation inflames the urinary tract. The finding underscores why the modified grading criteria matter, since disentangling treatment effects from pre-existing conditions is essential for honest toxicity reporting. It also hints at a practical implication for future trials—baseline urinary function may need to be a stratification factor when comparing fractionation schedules across institutions.

How does this compare with photon-based alternatives? The evidence base for shorter prostate radiotherapy is already strong: randomized trials of hypofractionated and ultra-hypofractionated photon therapy, including the HYPO-RT-PC trial of ultra-hypofractionated treatment, have confirmed efficacy comparable to conventional schedules. But acute toxicity data have been less favorable. A pilot study of ultra-hypofractionated intensity-modulated radiation therapy delivering 54 Gy in 15 fractions reported acute grade 2 genitourinary toxicity in 21 percent of patients—more than double the 8 percent seen in the proton trial. Earlier proton work by Nakajima’s group using 60 to 63 Gy in 20 to 21 fractions reported a 5.9 percent rate, and carbon-ion radiotherapy studies using the same 12-fraction, 51.6 Gy regimen achieved rates of 3 to 4 percent. Because carbon ions and protons differ fundamentally in physical characteristics and biological modeling, the question of whether the carbon-ion schedule could be safely transplanted to proton therapy had lacked prospective evidence—until now. A related phase II effort by Iwata and colleagues reported a 6.3 percent incidence using similar modified criteria in a 300-patient proton cohort, closely mirroring the present result.

The study has acknowledged limitations. It was conducted at a single institution, and patients with severe baseline urinary symptoms were excluded, which ensures a clean read on radiation-induced toxicity but limits generalizability to men with poor baseline urinary function. The current report covers only acute toxicity within three months; late genitourinary and gastrointestinal effects, local control rates, and biochemical recurrence-free survival await the ongoing expansion cohort, which targets 300 evaluable patients. Still, the early signal is compelling: a three-week proton regimen that matches the safety profile of far longer schedules, spares the bowel entirely in the acute setting, and returns patients to their lives weeks earlier. If the long-term data hold, the combination of the Bragg peak’s physics, hypofractionation’s radiobiology, and hydrogel spacer technology may redefine what men can expect from curative prostate radiotherapy—fewer visits, fewer side effects, and no compromise on the medicine itself.

Subject of Research: Acute genitourinary toxicity of hypofractionated proton beam therapy for localized prostate cancer

Article Title: Analysis of acute genitourinary toxicity in hypofractionated proton beam therapy for localized prostate cancer

Article References: Yang, W., Mizoe, J., Osaka, Y., Miyabe, Y., Seki, H., Nakamura, H., Sugawara, H., Miyajima, N., Iwata, H., Hashimoto, T., & Komaki, R. (2026). Analysis of acute genitourinary toxicity in hypofractionated proton beam therapy for localized prostate cancer. Holistic Integrative Oncology, 5(1), Article 35. https://doi.org/10.1007/s44178-026-00246-z

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00246-z

Keywords: prostate cancer, proton beam therapy, hypofractionation, genitourinary toxicity, radiation oncology, Bragg peak, CTCAE, androgen deprivation therapy, benign prostatic hyperplasia, SpaceOAR, clinical trial, urinary frequency

CIPN is a debilitating condition in which chemotherapy drugs damage the peripheral nerves, most often those serving the hands and feet. Patients typically experience numbness, tingling, burning pain, and loss of fine motor control. In severe cases, the symptoms persist for months or years after treatment ends, and there is currently no approved drug that reliably prevents or reverses the damage. Because paclitaxel, a mainstay taxane chemotherapy for breast cancer, is among the most neuropathy-inducing agents in clinical use, the search for a practical preventive measure has become a major priority in supportive oncology care.

The logic behind cryotherapy is elegantly straightforward. When a patient’s hands and feet are cooled during the infusion of chemotherapy, blood vessels in those extremities constrict, a process known as vasoconstriction. This reduces local blood flow, which in turn limits the amount of drug delivered to the small nerve fibers in the fingers and toes. Cooling also slows metabolic activity in nerve tissue and may reduce the cellular uptake of taxane molecules, further protecting the delicate axons that transmit sensation. The result is a physical barrier of sorts—cold-induced starvation of the drug at precisely the sites where neuropathy strikes first.

To test whether this mechanism translates into real clinical benefit, the research team searched six major databases—Scopus, PubMed/MEDLINE, ProQuest, ScienceDirect, SAGE Journals, and the Cochrane Library—from inception to July 17, 2025, without imposing date limits or restricting inclusion to randomized designs. The protocol was prospectively registered in PROSPERO before the final search update, a practice that helps guard against selective reporting. The team ultimately included fourteen studies: twelve randomized controlled trials and two retrospective cohort studies, all involving breast cancer patients receiving paclitaxel or nab-paclitaxel with cryotherapy as the primary preventive intervention.

The headline findings come from the comparative double-arm analyses, which directly compared cryotherapy against no cooling or alternative care. Patients who used cryotherapy had roughly 55 percent lower odds of developing moderate to severe neuropathy, measured as CTCAE Grade 2 or higher, with a relative risk of 0.45 and a 95 percent confidence interval of 0.27 to 0.77, a statistically significant result. Sensory neuropathy—the numbness and tingling that most often impair daily function—was reduced even more dramatically, with a relative risk of 0.35. On a second validated instrument, the Patient Neurotoxicity Questionnaire, the risk of reaching grade D or higher total scores fell to just 0.24 of the comparator risk, again statistically significant. Motor neuropathy, by contrast, showed no significant reduction, a finding the authors note honestly rather than glossing over.

Statistical heterogeneity across the comparative trials was low to moderate, which lends credibility to the pooled estimates. Risk of bias was assessed using the Cochrane RoB 2 tool for randomized studies and ROBINS-I for the non-randomized cohorts, while the certainty of the evidence was graded with the GRADE framework. This methodological rigor matters, because meta-analyses of supportive-care interventions are frequently criticized for combining heterogeneous protocols and outcome measures. Here, the authors took the additional step of separating comparative outcomes from single-arm proportions, treating the latter as very low-certainty, purely descriptive evidence rather than folding them into the efficacy estimates.

That separation proved important. The single-arm studies, which reported neuropathy incidence in cryotherapy users without a control group, yielded a pooled CTCAE Grade 2 or higher proportion of 0.20, but with high heterogeneity and no comparator, this figure cannot demonstrate efficacy. Similarly, pooled tolerability outcomes—any adverse event at 19 percent, cold intolerance at 16 percent, and discontinuation of cryotherapy due to side effects at just 2 percent—are non-comparative and highly heterogeneous. The authors explicitly caution that these descriptive estimates should not be interpreted as proof of safety or effectiveness, a level of statistical humility that is refreshingly rare in the field.

Two clinically crucial outcomes remain unresolved. Chemotherapy dose reduction, which matters because neuropathy often forces oncologists to cut treatment short, showed a relative risk of 0.43 in favor of cryotherapy, but this estimate rested on only two studies with a confidence interval crossing unity and a p-value of 0.109. Treatment discontinuation due to neuropathy showed an even larger apparent benefit, with a relative risk of 0.22, yet the p-value of 0.163 and wide confidence intervals mean the result is underpowered and inconclusive. These are precisely the outcomes that would matter most to patients and oncologists alike, and the authors are candid that larger trials are needed before any firm claims can be made.

The practical appeal of cryotherapy is hard to overstate. Unlike pharmacological candidates such as duloxetine, which carries its own side-effect profile, cooling devices are inexpensive, non-invasive, and require no systemic exposure. The low discontinuation rate of 2 percent suggests that most patients can tolerate the discomfort of wearing frozen gloves and socks for the duration of an infusion, even if cold intolerance affects roughly one in six. For a therapy that could spare a substantial fraction of breast cancer patients from chronic numbness and pain, the risk-benefit calculus appears favorable on its face.

Still, the authors urge cautious clinical interpretation. The evidence base, while promising, is built on trials with variable cooling protocols, differing outcome instruments, and limited power for the outcomes that matter most. Standardized intervention parameters—exact temperatures, duration of cooling, and timing relative to drug infusion—have yet to be established, and until large, well-designed randomized trials confirm the effects on dose intensity and treatment completion, cryotherapy should be viewed as a promising but not yet definitive preventive strategy. What the current analysis does establish is that the biological rationale is sound, the comparative signal is consistent, and the barrier to testing at scale is remarkably low. In a field where patients have long been told to simply endure the tingling, the prospect that a pair of frozen gloves might protect the nerves that matter most is a finding worth taking seriously.

Subject of Research: Cryotherapy for preventing chemotherapy-induced peripheral neuropathy in breast cancer patients treated with paclitaxel

Article Title: Cryotherapy for preventing chemotherapy-induced neuropathy in breast cancer patients treated with paclitaxel: a systematic review and meta-analysis

Article References: Prajoko, Y. W., Tjandra, K. C., Respati, D. R. P., Ar, A., Bulandari, B. L. A., Aryasatya, D. P., Rahmani, K., & Bima, R. C. S. (2026). Cryotherapy for preventing chemotherapy-induced neuropathy in breast cancer patients treated with paclitaxel: a systematic review and meta-analysis. BMC Cancer. https://doi.org/10.1186/s12885-026-16971-7

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16971-7

Keywords: cryotherapy, chemotherapy-induced peripheral neuropathy, breast cancer, paclitaxel, nab-paclitaxel, meta-analysis, systematic review, sensory neuropathy, supportive oncology, taxane chemotherapy, CTCAE, nerve protection